This bill amends existing law (RCW 72.09.780 and 2025 c 424 s 1912) to authorize "the department" to acquire, receive, possess, sell, resell, deliver, dispense, distribute, and otherwise engage in activities that constitute the practice of pharmacy or wholesale distribution with respect to abortion medications. It requires the department to establish and operate a program to deliver, dispense, and distribute those medications and allows the department to do so for the benefit of any person, whether or not the person is in custody or under supervision. The statute requires the department to follow applicable laws and licensing requirements but exempts actions taken under chapter 195, Laws of 2023 from obtaining a wholesaler's license as provided in RCW 18.64.046. When selling, delivering, or distributing to a health care provider or health care entity, the department may do so only to providers or entities that will use the medications for reproductive health care, including abortion care or medical management of early pregnancy loss. The department must coordinate with the Department of Health to identify recipients and prioritize bulk distribution, including to Indian health care providers, and may but is not required to obtain payment for these services. The bill includes definitions for terms such as "abortion medications," "health care provider," and "health care entity" and takes effect immediately under an emergency clause. Legally, this is a procedural and programmatic change to existing law that creates authority for a state department to handle and distribute specified medications and includes a specific licensing exemption; it does not create a new crime or change criminal penalties in the extracted text. The text repeatedly refers to "the department" without naming which agency, the final pricing or fee policy appears unclear in the available text, and the bill's interactions with the referenced 2023 law and other cited provisions are not shown in these extracts.

The practical effect is that a state department will be able to buy, possess, and run a program to deliver and distribute abortion medications such as mifepristone and misoprostol to health care providers and to benefit people (including those not in custody), with bulk distribution prioritized to Indian health care providers and done in coordination with the Department of Health; the department can charge for the drugs but is not required to and is exempt from a wholesaler’s license for these actions under the referenced 2023 law. Health care providers and clinics are likely to see easier access and an additional supply route for reproductive care drugs, while the unnamed department takes on new operational responsibilities, logistical and compliance costs, and the practical duty to screen recipients so the medications are used only for reproductive health care. Important uncertainties remain: the text here does not identify which specific agency is “the department,” it does not show final rules or pricing policy (some pricing language appears deleted), and the bill refers to other statutes whose interactions are not included, so funding sources, budget impacts, and exact recipient screening or oversight practices are not clearly defined.